Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19

This article has been Reviewed by the following groups

Read the full article See related articles

Abstract

No abstract available

Article activity feed

  1. SciScore for 10.1101/2020.05.20.20108555: (What is this?)

    Please note, not all rigor criteria are appropriate for all manuscripts.

    Table 1: Rigor

    Institutional Review Board StatementIRB: Ethics statement: This study was approved by the Institutional Review Board of Kyung Hee University Hospital (no. KHUH 2020-04-067).
    Consent: The requirement for informed consent was waived by the institutional review board because de-identified information was used for the analyses.
    Randomizationnot detected.
    Blindingnot detected.
    Power Analysisnot detected.
    Sex as a biological variablenot detected.
    Cell Line Authenticationnot detected.

    Table 2: Resources

    Experimental Models: Cell Lines
    SentencesResources
    COVID-19 diagnosis was defined as ICD-10 diagnosis codes B34.2, B97.2, U18, U18.1, or U07.x.
    B97.2
    suggested: RRID:CVCL_B972)
    Software and Algorithms
    SentencesResources
    Statistical analyses were performed using SAS version 9.4 (SAS Institute, Cary, NC, US), and p< 0.05 was considered statistically significant.
    SAS Institute
    suggested: (Statistical Analysis System, RRID:SCR_008567)

    Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).


    Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:
    This may have been because the effects on the long-term clinical course and prognosis were not considered; owing to the limitation of our study design, only the short-term clinical outcomes of the subjects were analyzed. The synergistic effect of the combination of DPP-4i and RAS blockade could not be explained for the same reason. This study has other limitations. Firstly, since this study was based on claim data, it was difficult to obtain detailed clinical information about the patients. In particular, it was difficult to evaluate the patient’s demographic characteristics, laboratory tests, images, and detailed clinical course information. Secondly, the study results demonstrated that DPP-4i users exhibited better clinical outcomes; however, these results did not imply a clear causal relationship. Thirdly, it was difficult to predict the long-term clinical course and prognosis of the patients because our analysis was only for short-term clinical outcomes. Fourthly, this study may be difficult to generalize with respect to other countries as it was conducted in Korea, where the proportion of severely ill patients and fatalities related to COVID-19 is lower than that in other countries. Lastly, further research is needed because a clear mechanism for explaining the facts obtained in this study has not been established. These limitations necessitate careful interpretation and generalization of the results. However, this study was based on a large dataset representative of the...

    Results from TrialIdentifier: No clinical trial numbers were referenced.


    Results from Barzooka: We did not find any issues relating to the usage of bar graphs.


    Results from JetFighter: We did not find any issues relating to colormaps.


    Results from rtransparent:
    • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
    • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
    • No protocol registration statement was detected.

    About SciScore

    SciScore is an automated tool that is designed to assist expert reviewers by finding and presenting formulaic information scattered throughout a paper in a standard, easy to digest format. SciScore checks for the presence and correctness of RRIDs (research resource identifiers), and for rigor criteria such as sex and investigator blinding. For details on the theoretical underpinning of rigor criteria and the tools shown here, including references cited, please follow this link.